2026 CSTE Syphilis Case Updates

The 2026 CSTE Syphilis Case Definition Updates mark a major shift in how syphilis is diagnosed
and managed in the United States. Effective January 1, 2026, these guidelines expand laboratory
testing criteria, revise definitions for acquired and congenital syphilis, and update protocols for
neuro/ocular/otic syphilis. Intravenous penicillin is now emphasized for neurosyphilis, and a new
“Supportive Laboratory Evidence” category helps identify cases when standard tests are
unavailable. For congenital syphilis, criteria now include specific CSF, serum, and X-ray findings, as
well as advanced diagnostic methods like NAAT and immunohistochemistry. The term “Acquired
Syphilis” replaces “Adult Syphilis” to reflect cases in children and young adults. These updates aim
to improve diagnostic accuracy, simplify processes, and incorporate advancements in testing
technologies, ultimately enhancing public health surveillance and syphilis management.

Impact of the Updates

The impact of these updates is substantial for healthcare providers and public health systems. By
clarifying diagnostic criteria and expanding laboratory testing options, the guidelines enable earlier
and more accurate detection of syphilis, especially in vulnerable populations such as infants and
children. Standardized protocols help streamline case reporting and surveillance, making it easier for
public health professionals to track trends and respond to outbreaks. The inclusion of new diagnostic
technologies ensures the guidelines remain relevant as testing methods evolve, while the removal of
ambiguous categories and the introduction of supportive evidence pathways reduce uncertainty in
case classification. Ultimately, these changes are expected to improve patient outcomes, reduce the
incidence of congenital syphilis, and strengthen the overall response to syphilis at the community
and national levels.

Recent Statistics on Syphilis Cases

Syphilis rates in the United States have reached levels not seen since the 1950s. In 2024, there
were more than 2.2 million reported sexually transmitted infections, with congenital syphilis cases
rising for the 12th consecutive year—nearly 4,000 cases reported in 2024, representing a 700%
increase since 2015. While primary and secondary syphilis cases declined by 22% in 2024, the
overall burden remains staggering. Younger individuals (ages 15–24) account for about half of all
STI infections per year, and congenital syphilis continues to disproportionately affect vulnerable
populations, including Black, Hispanic, and low-income groups in areas with poor healthcare access.

Implementation Challenges

Implementing these new guidelines presents several challenges. Data gaps and reporting delays,
especially in under-resourced clinics, can affect the accuracy of outcome tracking and timely
decision-making. Retaining high-risk populations—such as pregnant individuals experiencing
homelessness, substance use, or incarceration—in follow-up efforts is difficult, limiting the ability to

measure long-term outcomes. Not all healthcare providers may adopt the screening protocols
uniformly, leading to inconsistent implementation across regions. Resource constraints, including
sustaining mobile health units, staffing, and medication supply, pose ongoing difficulties without long-
term funding commitments. External factors such as policy changes, drug shortages, or public health
emergencies (e.g., pandemics) can disrupt program activities or shift priorities. Addressing these
challenges requires sustained investment in public health infrastructure, automation, interlaboratory
data sharing, and efforts to overcome social determinants of health.

Recommendations for Healthcare Providers

• Screen all individuals aged 18–49 for syphilis at least once as part of routine healthcare, and screen all pregnant people three times during pregnancy (first prenatal visit, third trimester, and at delivery).
• Prioritize Bicillin L-A (penicillin G benzathine) for pregnant patients and babies with congenital syphilis, especially during anticipated shortages.
• Use point-of-care and advanced molecular tests (e.g., NAAT, PCR) for rapid and accurate diagnosis, particularly in resource-limited settings.
• Ensure timely reporting of syphilis cases to local health authorities within required timeframes to support surveillance and outbreak response.
• Engage in partner notification and management to interrupt transmission chains.
• Stay updated with the latest CDC and state guidelines, and utilize available toolkits and job aids for clinical decision-making.

Future Trends in Syphilis Management

Looking ahead, syphilis management is poised for significant advancements:

• Alternative antibiotics (e.g., ceftriaxone, doxycycline, cefixime, dalbavancin) are being explored for patients with penicillin allergies or resistance, though penicillin remains the gold standard.
• Shortened penicillin regimens and new dosing strategies are under investigation to simplify treatment.
• Advanced molecular diagnostics, including rapid point-of-care tests and PCR, are improving early detection and case management, especially for congenital syphilis and in high-risk populations.
• Vaccine research is ongoing, with the goal of long-term prevention.
• Integration of syphilis services into primary healthcare, targeted prevention for high-risk groups, and global research collaborations are expected to enhance accessibility, early detection, and treatment.
• The World Health Organization and other agencies are prioritizing research to address gaps in diagnosis, prevention, and management, aiming for a syphilis-free future.